Sponsor

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

The Netherlands Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

About the sponsor

Research activity includes HER2-positive breast cancer, triple-negative breast cancer, and oligometastatic breast cancer, with strong attention to neoadjuvant treatment, adjuvant therapy, and immune checkpoint inhibition. The portfolio also covers residual disease after systemic treatment and treatment strategies for metastatic breast cancer.

HER2-targeted therapy
Immunotherapy in TNBC
Oligometastatic disease
Residual disease management

Work in this area reflects interest in combining systemic agents with surgery and other local treatments for breast cancer subtypes with limited treatment options.

About Specializations

Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting runs clinical trials in conditions such as Colorectal cancer metastatic, Malignant melanoma, Penile cancer, Colorectal cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

47 clinical trials

Triple negative breast cancer

Recruiting

Registered drugNo placebo

Study of pembrolizumab, capecitabine, or olaparib in patients with early-stage triple negative breast cancer and remaining disease after initial treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Registered drugNo placebo

Study of nivolumab and ipilimumab immunotherapy for organ preservation in patients with advanced head and neck squamous cell carcinoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Breast cancer

Recruiting

Registered drugNo placebo

Study of olaparib and chemotherapy combination in stage III breast cancer patients with HER2-negative, hormone receptor impaired or deficient disease

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Glioma

Recruiting

Registered drugNo placebo

Study on Bevacizumab and Dexamethasone for Treating Brain Radiation Damage in Patients with High-Grade Glioma or Brain Metastases

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Squamous cell carcinoma of skin

Recruiting

Registered drugNo placebo

Study of nivolumab and ipilimumab combination therapy as an alternative to surgery and radiation in patients with skin squamous cell carcinoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Breast cancer+2

Recruiting

Registered drugNo placebo

Study on Using Perflubutane for Sentinel Node Detection in Patients with Breast Cancer, Melanoma, or Head and Neck Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Perflubutane
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Breast cancer stage III+2

Recruiting

Registered drugNo placebo

Study on Pre-Operative Treatment for Breast Cancer Using Nivolumab, Ipilimumab, and Relatlimab for Patients with Breast Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Cancer surgery

Recruiting

Registered drugNo placebo

Study on Reducing Fluid Use During Cancer Surgery with Argipressin for Patients with Disseminated Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Argipressin
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Contact Research Centre

Renal cancer+2

Recruiting

InvestigationalNo placebo

Study on Using EMI-137 for Intraoperative Visualization in Patients with Penile and Tongue Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ac-Ala-Gly-Ser-Cys(1)-Tyr-Cys(2)-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys(2)-Trp-Cys(1)-Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys(Unk)-Nh2 Conjugated To Cy5 Dye
Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting